News | Structural Heart | July 13, 2020

Edwards Lifesciences and Abbott Settle Transcatheter Mitral Valve Device Patent Litigation

Abbott will receive a one-time payment and ongoing payments in connection to Edward's Pascal device sales

A comparison of the Edwards Pascal (left) and the Abbott MitraClip used for transcatheter mitral and tricuspid valve leaflet repairs. The two companies settled patent litigation regarding the devices today.

July 13, 2020 — Edwards Lifesciences Corp. and Abbott Vascular announced the two companies have reached an agreement to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. 

The agreement will result in the dismissal of all pending cases or appeals in courts and patent offices worldwide, and includes a provision that the parties will not litigate patent disputes with each other in the field of transcatheter mitral and tricuspid repair and replacement products for the 10-year duration of the agreement. The injunctions currently in place against the sale of Edwards' transcatheter mitral and tricuspid repair system will be lifted.  

In connection with this agreement, Abbott will receive a one-time payment and ongoing payments based on the sales of the Edwards Pascal transcatheter valve repair system through 2025, as well as a potential sales milestone payment in 2026. The Pascal is very similar in design to the Abbott MitraClip device that is used for transcatheter mitral and tricuspid valve leaflet repairs.

Edwards said considers this agreement a positive development, as it allows the company to fully dedicate time and resources to helping patients.

Details of the settlement are confidential.

 

Related Transcatheter Mitral Valve Device Content:

Developments in Transcatheter Mitral Valve Replacement

Transcatheter Tricuspid Valve Repair Clip Device Cleared in Europe

New Study Looks at MitraClip use in Moderate Surgical Risk Patients

Edwards Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe

Edwards Announces Research Milestones for Pascal Transcatheter Mitral Valve Program
 

 

Related Content

News | Cardiovascular Business

August 17, 2022 — Memorial Healthcare System, a South Florida-based academic medical center, has added a diverse trio of ...

Home August 17, 2022
Home
News | Cardiovascular Business

August 16, 2022 — A study of cardiology programs indicates that patients’ documented do-not-resuscitate (DNR) ...

Home August 16, 2022
Home
News | Cardiovascular Business

August 16, 2022 — Two leaders in cardiovascular disease science, research and education, the American Heart Association ...

Home August 16, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Diagnostic and Interventional Cardiology (DAIC) maintains more than 30 comparison charts of product specifications from ...

Home August 12, 2022
Home
News | Cardiovascular Business

August 12, 2022 — Clarius Mobile Health, a leading provider of high-definition wireless ultrasound systems, announced ...

Home August 12, 2022
Home
News | Cardiovascular Business

August 10, 2022 — On July 27, ASNC joined a coalition of more than 100 medical societies urging Congress to pass ...

Home August 10, 2022
Home
News | Cardiovascular Business

August 5, 2022 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home August 05, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional ...

Home August 01, 2022
Home
News | Cardiovascular Business

July 22, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias ...

Home July 22, 2022
Home
News | Cardiovascular Business

July 19, 2022 — On July 7, the Centers for Medicare & Medicaid Services (CMS) released the 2023 Medicare Physician Fee ...

Home July 19, 2022
Home
Subscribe Now